From staff reports | Aug 29, 2016
Ohio University has executed an agreement with Eli Lilly to become part of the Open Innovation Drug Discovery (OIDD) Program. The OIDD Program seeks to leverage the tools and expertise at Eli Lilly to advance drug discovery research by university scientists and together identify the next generation of therapeutics that will improve patients’ lives.
The OIDD Program opens the door for Ohio University researchers to access Lilly’s cloud-based computer simulation tools, in vitro data screening, and a library of compounds from Lilly as well as other collaborative users while keeping Ohio University intellectual property secure. In addition to seeking opportunities that align with its own strategic areas of focus, including cardiovascular disease, oncology, diabetes, neuroscience, musculoskeletal diseases, and immunology, Lilly also has partnered with global health organizations to screen compounds against neglected and tropical diseases.
The OIDD Program will be administered through the Ohio University Technology Transfer Office, which is responsible for:
- Educating investigators about the program;
- Reviewing proposals and determining whether they meet the eligibility criteria;
- Working with investigators to submit projects to the program; and
- Ensuring the requirements of the agreement are met for each submission.
Individuals interested in participating in the program or who have additional questions should contact Korie Counts, technology commercialization manager and affiliation coordinator for the OIDD Program, at (740) 593-0977 or counts@ohio.edu.
Comments